Investor Presentaiton
KRAZATI (adagrasib)
Differentiated KRASG12C Inhibitor with Broad Development Program to Maximize Potential for Patients
2L+ Lung Cancer
Monotherapy
-7,000
U.S. Patients
1L Lung Cancer
Combination with Pembro
or Pembro and
Chemotherapy
~15,500
U.S. Patients
Colorectal Cancer
CNS Penetrant
Monotherapy /
Combination with
Cetuxibmab
~4,000
U.S. Patients
Combinability with
PD-1 and Chemo
Approved in December 2022
Ongoing confirmatory Phase
3 trial topline readout in 1H
2024
TPS ≥50% Adagrasib + PD-1
Phase 3 enrolling by YE 2023
TPS <50% Adagrasib + PD-1 +
chemotherapy combination
KRYSTAL-17 readout in 2024
3L+ CRC filing by YE 2023
Phase 3 study in 2L+ CRC
ongoing top-line report PFS
and interim OS in 2024
Improved Half-Life
and PK Profile
Ill Bristol Myers Squibb™
Not for Product Promotional Use
9View entire presentation